RM-END / Endocrine and peptide-hormone analogs
Pasireotide
Also known as: Signifor · Signifor LAR · SOM230 · Pasireotide pamoate
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Pasireotide is a synthetic cyclohexapeptide somatostatin analog. Its immediate- and long-acting products use different formulations and must not be collapsed into one material record.
Evidence position
Regulated finished products and human evidence support Grade A for the labeled presentations.
What the record does not establish
The label does not authenticate another pasireotide sample or establish equivalence across salts and release systems.
Sources
- 01Pasireotide compound recordPubChem
- Shows
- Registry identity, structure, formula and synonyms for pasireotide
- Does not show
- Does not determine salt, release system, presentation or lot quality
- 02Signifor LAR prescribing informationDailyMed / U.S. National Library of Medicine
- Shows
- Current U.S. label for a defined pasireotide pamoate microsphere product
- Does not show
- Does not qualify another salt, release profile, concentration or source
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Pasireotide
- CID
- 9941444
- Formula
- C58H66N10O9
- Mass
- 1047.2
PUBMED / FOUND RECORDS
- Acromegaly.Nature reviews. Disease primers / 2019 Mar 21PMID 30899019 / DOI 10.1038/s41572-019-0071-6
- Pasireotide. / 2012PMID 31644171
- Pasireotide. / 2006PMID 31145573
- New Trends in Treating Cushing's Disease.TouchREVIEWS in endocrinology / 2024 OctPMID 39526050 / DOI 10.17925/EE.2024.20.2.3
- Update and Practical Recommendations for the Use of Medical Treatment of Cushing Syndrome.Endocrine reviews / 2026 May 13PMID 41489578 / DOI 10.1210/endrev/bnaf042
CLINICALTRIALS.GOV / FOUND RECORDS
- An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With AcromegalyCOMPLETED / PHASE2 / Novartis PharmaceuticalsNCT00171730 / DIRECT intervention MATCH: Pasireotide
- Treatment of Hypoglycemia Following Gastric Bypass SurgeryCOMPLETED / PHASE4 / Zealand University HospitalNCT02527993 / DIRECT intervention MATCH: Pasireotide
- Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung CancerUNKNOWN / PHASE2 / South Florida Veterans Affairs Foundation for Research and EducationNCT01417806 / DIRECT intervention MATCH: Pasireotide
- Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's DiseaseCOMPLETED / PHASE2 / Novartis PharmaceuticalsNCT00171951 / DIRECT intervention MATCH: Pasireotide
- Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal CarcinomatosisTERMINATED / PHASE2 / Gustave Roussy, Cancer Campus, Grand ParisNCT04826432 / DIRECT intervention MATCH: Pasireotide